Skip to main content
SEOUL PHARMA CO.,LTD logo

SEOUL PHARMA CO.,LTD — Investor Relations & Filings

Ticker · 018680 ISIN · KR7018680009 KO Manufacturing
Open in API
Filings indexed 151 across all filing types
Latest filing 2019-03-26 Major Shareholding Noti…
Country KR South Korea
Listing KO 018680

About SEOUL PHARMA CO.,LTD

http://www.seoulpharmaceuticals.com/

Seoul Pharma Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products. The company specializes in innovative drug delivery systems, with a core competency in Orally Disintegrating Film (ODF) technology. Its product portfolio includes a wide range of prescription and over-the-counter medications. Key therapeutic areas cover cardiovascular and respiratory systems, as well as anti-infective agents such as antibacterials, antifungals, and antivirals. The company also produces vitamins and antibiotics, aiming to improve health outcomes through its cutting-edge technological capabilities.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, including reasons for changes such as director resignations. This falls under the category of Major Shareholding Notification.
2019-03-26 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (Annual General Meeting). It details the approval of financial statements, dividend resolutions, and the election of directors and auditors. This falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports the outcome of shareholder votes at a general meeting.
2019-03-22 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion, key financial data, and auditor information for Seoul Pharma. While it contains financial data, it is a formal notification of the submission of the audit report to the regulatory body, rather than the full annual report (10-K) or a standalone audit report document. Given the short, structured nature of the filing and its purpose as a regulatory disclosure of the audit report's availability, it fits the 'Report Publication Announcement' (RPA) category. FY 2018
2019-03-14 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on the Status of Large Shareholdings' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as the 5% rule filing). It details changes in share ownership by a major shareholder (Atinum Investment) in a listed company (Seoul Pharma). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) as it tracks significant ownership thresholds and changes.
2019-03-08 Korean
주주총회집중일개최사유신고
Regulatory Filings Classification · 95% confidence The document is a formal notification filed by Seoul Pharma regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the reasons for this scheduling conflict and provides details on the meeting date and notice date. Since this is a regulatory disclosure regarding the logistics of a shareholder meeting rather than the meeting materials themselves or the voting results, it falls under the general regulatory filing category.
2019-03-05 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Seoul Pharma. It contains the meeting agenda, details on voting rights, and management's report on business activities and financial statements (balance sheet, income statement, etc.) for the 33rd fiscal year. While it contains financial data, it is primarily a proxy statement/notice for shareholders to attend the AGM and vote on agenda items (directors, auditors, financial approval). In the context of regulatory filings, this is classified as a Proxy Solicitation & Information Statement.
2019-03-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.